Empreses emergents
2009
BIONURE FARMA SL Promoció de la neuroprotecció: agonistes de SGK de primera classe per a afeccions oftalmològiques rares Empresa integrada amb Iproteos per formar Accure Therapeutics
Adreça
Carrer de Sant Joan de Malta 145, 08018 Barcelona, Espanya
Dades financeres
Propietat CERCA
Altres accionistes públics catalans
Logotip
Àrees d'estat i deeptech
Estat de l'empresa i àrees de tecnologia profunda de l'empresaEstat de l'empresa
Àrea DeepTech
Informació sobre la spin-off
Descripció de l'empresa
Bionure is a clinical stage company developing first-in-class SGK agonists for the treatment of rare ophthalmological diseases for which no treatment options are nowadays available. We focus in particular in two conditions in which patients suffer from significant vision impairment: acute optic neuritis and neuromyelitis optica.
With these patients in mind, we have built an extraordinary committed team of experts in neuro-ophthalmology and neuro-inflammation, passionate about bringing meaningful therapies to society with the aim of changing the life of thousands of people.
With these patients in mind, we have built an extraordinary committed team of experts in neuro-ophthalmology and neuro-inflammation, passionate about bringing meaningful therapies to society with the aim of changing the life of thousands of people.
Descripció del producte
Our lead candidate BN201 has been granted orphan designation for optic neuritis in Europe and the United States and has shown compelling evidence of neuroprotective and remyelinating activity in several animal models. Bionure is currently undertaking a Phase 1 clinical trial of the compound BN201 in the United Kindom.
Promoting Neuroprotection: First-in-class SGK agonists for rare ophthalmological conditions
Addressing Optic Neuritis, Neuromyelitis Optica and Multiple Sclerosis by promoting neuroprotection and remyelination
Promoting Neuroprotection: First-in-class SGK agonists for rare ophthalmological conditions
Addressing Optic Neuritis, Neuromyelitis Optica and Multiple Sclerosis by promoting neuroprotection and remyelination